Evidence map›Paper›PMID 32113976›Full record

ArticleJournal of pharmaceutical sciences2020

Vaginal Suppositories Containing SHetA2 to Treat Cervical Dysplasia: Pharmacokinetics of Daily Doses and Preliminary Safety Profile.

Sanjida Mahjabeen, Manolya Kukut Hatipoglu, Stanley D Kosanke, David Garcia-Contreras, Doris M Benbrook, Lucila Garcia-Contreras

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of pharmaceutical sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. SHetA2 Attack on Mortalin and Colleagues in Cancer Therapy and Prevention.Frontiers in cell and developmental biology · 2022
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 3 countries.

Sanjida MahjabeenDepartment of Pharmaceutical Sciences, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104.
Manolya Kukut HatipogluDepartment of Pharmaceutical Sciences, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104; Genetics and Bioengineering Department, Yeditepe University, Istanbul, Turkey.
Stanley D KosankeDepartment of Comparative Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104.
David Garcia-ContrerasMedicina Veterinaria, Facultad de Estudios Superiores, Cuautitlán, Mexico.
Doris M BenbrookDepartment of Pharmaceutical Sciences, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104; Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104.
Lucila Garcia-ContrerasDepartment of Pharmaceutical Sciences, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104. Electronic address: lucila-garcia-contreras@ouhsc.edu.
University of Oklahoma Health Sciences Center · USUniversidad de Cuautitlán Izcalli · MX

Funding

Targeting HPV Consequences in a Cervical Cancer Clinical TrialR01CA200126 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI BENBROOK, DORIS MANGIARACINA, MOORE, KATHLEEN N. · 2016 to 2021
$2.1M
NCI NIH HHS R01 CA200126
6 · The paper itself

Abstract

SHetA2 is a new drug with potential to treat cervical dysplasia, but only 0.02% of the dose is absorbed into the cervix after oral administration. By contrast, 23.9% of the dose is absorbed into the cervix after vaginal administration. This study determines the pharmacokinetic and pharmacodynamic parameters after daily vaginal doses of SHetA2 in suppositories and assesses its safety. Daily dosed mice maintained therapeutic concentrations of SHetA2 in the cervix for 65 h. The steady-state area under the curve concentration versus time (AUC

Indexed as

ThionesUterine Cervical DysplasiaAdministration, OralAnimalsArea Under CurveChromansDose-Response Relationship, DrugFemaleHalf-LifeHumansMiceSuppositories(((4-nitrophenyl)amino)(2,2,4,4-tetramethyl thiochroman-6-yl)amino) methane-1-thioneChromansSuppositoriesThionescervical dysplasiamultiple dose pharmacokineticspreclinical safety assessmentSHetA2vaginal drug delivery

Identifiers

PMID32113976
PMCPMC7247943
OpenAlexW3007917750

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.